source
- Pfizer strikes over $500M partnership with Enodia to develop Sec61-targeting small-molecule drugsPfizer's venture arm helped fund Enodia Therapeutics with a $25 million seed round earlier this year. The two companies have now announced a collaboration that could be worth more than $500 millio…
- Paragon Labs launches ninth biotech, Velaris Therapeutics, via reverse merger to bring cardiopulmonary drugs to AlaunosParagon Labs announced the creation of its ninth biotech company, Velaris Therapeutics, using a reverse‑merger approach it has refined over the past four years. The transaction was completed on Tu…